Sanford-Burnham Medical Research Institute: Making Sure New Drugs Aren't Lost In Translation
This article was originally published in Start Up
Executive Summary
With a metabolic-disease deal with Takeda Pharmaceuticals already under its belt, Sanford Burnham aims to extend its academic prowess to more business-oriented opportunities. Chief Business Officer Paul Laikind, PhD, aims to inject entrepreneural blood into Sanford-Burnham's scientific muscle.
You may also be interested in...
Vanderbilt's Neuroscience Unit Operates Like A Biotech
A small drug-discovery shop within Vanderbilt University Medical Center shows how a focused approach can lead to top-notch results in the so-called translational research space.
Spurred By Necessity, Industry And Academia Are Learning To Share
After a prior era of failed collaborations, industry and academia are increasingly joining forces in ways that better accommodate each others’ capabilities and goals – and, they hope, will create more value and ultimately greater improvements to human health.
Spurred By Necessity, Industry And Academia Are Learning To Share
After a prior era of failed collaborations, industry and academia are increasingly joining forces in ways that better accommodate each others’ capabilities and goals – and, they hope, will create more value and ultimately greater improvements to human health.